Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?
The treatment landscape of advanced hepatocellular carcinoma (HCC) has broadened with immune checkpoint inhibitors (ICIs) setting a novel standard of care. With the increased number of therapies either in first or in further line, disentangling the possible treatment sequences has become much more c...
Main Authors: | Antonella Cammarota, Valentina Zanuso, Giulia Francesca Manfredi, Ravindhi Murphy, David James Pinato, Lorenza Rimassa |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-01-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/17588359221148029 |
Similar Items
-
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights
by: Cammarota A, et al.
Published: (2022-09-01) -
Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights
by: Rita Balsano, et al.
Published: (2023-03-01) -
New systemic treatment options for advanced cholangiocarcinoma
by: Valentina Zanuso, et al.
Published: (2024-09-01) -
Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma
by: Zanuso V, et al.
Published: (2023-10-01) -
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma
by: Manfredi GF, et al.
Published: (2023-11-01)